Insights

Get access to our latest news by becoming an Avulux Authorized Provider.

FDAAvulux Granted FDA De Novo Authorization, Creating the First Lens Classification for Migraine-Associated Light Sensitivity

Avulux Granted FDA De Novo Authorization, Creating the First Lens Classification for Migraine-Associated Light Sensitivity

An FDA-authorized lens for the light sensitivity that affects nearly 9 in 10 people with migraine. Miami, FL – August 24, 2026 – Avulux, the maker of clinically-proven precision light-filtering len...

Aug 24, 2026
Avulux, BluTech Partner on Next-Generation Enhanced Migraine Lens

Avulux, BluTech Partner on Next-Generation Enhanced Migraine Lens

Miami, Fla (January 7, 2026) – Avulux, the innovator behind the only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, and BluTech, a longstanding industr...

Jan 12, 2026
AvuluxThe Ultimate Guide to Migraine Management

The Ultimate Guide to Migraine Management

A Brief Overview of Migraine A migraine is “an episodic headache associated with certain features, such as sensitivity to light, sound, or movement” or “a recurring syndrome of headache associated ...

Jul 24, 2025
AvuluxAvulux-CTIP-Imagery

Avulux Added into the FDA-Funded Consortium for Technology & Innovation in Pediatrics (CTIP) Portfolio

Avulux, the innovator behind the only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, today announced that the Consortium for Technology & Innovatio...

Mar 24, 2025
Alliance NewsAvulux | PECAA

Avulux and PECAA Partner to Bring Migraine Solution Lenses to Private Practices

Avulux, the maker of the only clinically proven migraine light sensitivity lenses, and PECAA (Professional Eye Care Associates of America) are pleased to announce a partnership that now makes Avulu...

Jan 21, 2025
Patient CareMigraine light sensitivity relief with Avulux lenses

Avulux Patient Feedback: Get Your Patients Back to What They Love

Migraine is a genetic neurological disease that affects nearly 48 million people in the United States — that’s almost 1 in 5 patients in your practice. Around 90% of people with migraine experience...

Oct 15, 2024

White Glove Onboarding

Dedicated Avulux representatives are available to enable you and your team

Trusted by Over 1,400 ECPs

There are over 1,400 Avulux Authorized Providers globally

Ongoing Support & Resources

Avulux providers have access to our team and a suite of tools to help you better serve your patients

Over 50,000

Over 50,000 Avulux wearers are managing the impact of light on their lives.

Become an
Avulux Provider

Become an Avulux Provider

Indications for Use: Avulux® is an FDA-authorized, over-the-counter precision optical filter indicated to block light at 480 nm (high blue range) and 590 nm (red/amber range), while allowing light in the remaining visible color spectrum through, to decrease the impact of light sensitivity in patients diagnosed with episodic migraine aged 12 years and older. The use of Avulux should not alter the usual care therapy of patients diagnosed with episodic migraine, including medication usage.

Avulux is intended to be used as an adjunct to usual care for migraine, including medication. It is not intended to diagnose, treat, cure, or prevent migraine or any other disease and is not a substitute for professional medical advice, diagnosis, or treatment. Consult a qualified healthcare professional regarding migraine symptoms and treatment. Avulux is classified by the U.S. Food and Drug Administration as a Class I medical device under 21 CFR § 882.5811, product code QEO. De Novo request DEN250026.